Osteoimmunology

ETS1 regulates tissue-remodeling properties of specific fibroblast subtypes in the synovium, gut and cancer and thus emerges as a novel cross-tissue therapeutic target for modulation of pathogenic fibroblast activation.

Comprehensive review articles written by international experts are important to provide readers from diverse backgrounds with an expanding knowledge base.

Probiotic microorganisms such as Lactobacillus rhamnosus can protect from bone loss by enhancing levels of butyrate, which leads to the expansion of regulatory T cells. These stimulate CD8⁺ T cells to secrete WNT10b, a bone anabolic factor.

A variety of biologic DMARDs now exist for the treatment of rheumatoid arthritis, but we don’t really know how these drugs function in vivo. Can time-lapse intravital imaging distinguish the modes of action of DMARDs by comparing response to joint destruction in mouse models of arthritis?

Biologic agents targeting key proteins involved in bone homeostasis are revolutionizing the management of osteoporosis. New clinical data support the use of these novel therapies to rapidly increase bone mass and decrease the risk of fractures.